Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think?
John Gribben et al. • 6 Sep 2019
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al.
Outcomes of CLL patients following treatment with a covalent BTK and BCL2 inhibitor
Toby Eyre • 15 Jun 2022
The long-term efficacy of acalabrutinib-based regimens in patients with CLL
Matthew Davids • 12 Jun 2022
5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL
Othman Al-Sawaf • 11 Jun 2022